Enanta Pharmaceuticals | ENTA - Pre Tax Profit


Enanta Pharmaceuticals reported $-22.71M in Pre-Tax Profit for its fiscal quarter ending in December of 2024.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Amgen USD 2.08B 570M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD -178.9M 41.34M Jun/2026
AstraZeneca USD 4.81B 894M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 647.3M 269.6M Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 751.51M 407.91M Jun/2026
Insmed USD -11.37M 150.72M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
J&J USD 8.66B 839M Jun/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026